Corcept Therapeutics
Clinical trials sponsored by Corcept Therapeutics, explained in plain language.
A commercial-stage pharmaceutical company developing drugs for severe metabolic and psychiatric disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise against fatty liver disease in Mid-Stage trial Results expected Sep 2026 (estimated)
- New drug duo aims to fight Hard-to-Treat cancers Results expected Sep 2026 (estimated)
- New hope for ALS: experimental drug aims to slow muscle decline Results expected Oct 2026 (estimated)
- New drug miricorilant tested for fatty liver disease safety Results expected Oct 2026 (estimated)
- New drug shows promise for Long-Term control of cushing syndrome Results expected Dec 2026 (estimated) May already have reported ↗